Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zoetis Inc Cl A (ZTS)

Zoetis Inc Cl A (ZTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,288,224
  • Shares Outstanding, K 440,693
  • Annual Sales, $ 9,256 M
  • Annual Income, $ 2,486 M
  • EBIT $ 3,462 M
  • EBITDA $ 3,959 M
  • 60-Month Beta 0.97
  • Price/Sales 5.73
  • Price/Cash Flow 17.03
  • Price/Book 9.89

Options Overview Details

View History
  • Implied Volatility 28.44% (+1.16%)
  • Historical Volatility 48.94%
  • IV Percentile 55%
  • IV Rank 31.05%
  • IV High 46.55% on 04/07/25
  • IV Low 20.29% on 12/13/24
  • Expected Move (DTE 11) 4.25 (3.55%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 6,711
  • Volume Avg (30-Day) 3,708
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 66,667
  • Open Int (30-Day) 60,316
  • Expected Range 115.57 to 124.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.40
  • Number of Estimates 10
  • High Estimate 1.41
  • Low Estimate 1.38
  • Prior Year 1.40
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.25 +3.82%
on 11/19/25
129.58 -7.66%
on 12/01/25
-0.59 (-0.49%)
since 11/07/25
3-Month
115.25 +3.82%
on 11/19/25
152.12 -21.34%
on 09/09/25
-32.10 (-21.15%)
since 09/08/25
52-Week
115.25 +3.82%
on 11/19/25
181.85 -34.20%
on 12/13/24
-56.81 (-32.19%)
since 12/06/24

Most Recent Stories

More News
3 Cash-Producing Stocks with Exciting Potential

3 Cash-Producing Stocks with Exciting Potential

LRCX : 162.18 (+2.19%)
ZTS : 119.04 (+0.33%)
LYTS : 18.86 (+0.64%)
Zoetis Receives Health Canada Approval for Portelaâ„¢(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that Health Canada has approved Portela â„¢ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed...

ZTS : 119.04 (+0.33%)
How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.

XLV : 151.94 (-0.86%)
ZTS : 119.04 (+0.33%)
IDXX : 707.69 (-0.90%)
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster 1 Candidates, and Unmatched Scale and Capabilities ...

ZTS : 119.04 (+0.33%)
1 Oversold Stock Primed to Rebound and 2 We Find Risky

1 Oversold Stock Primed to Rebound and 2 We Find Risky

KAI : 281.58 (-2.24%)
ZTS : 119.04 (+0.33%)
SAIC : 98.77 (-1.83%)
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia ® (izenivetmab) for the reduction of pain associated with osteoarthritis...

ZTS : 119.04 (+0.33%)
Is Zoetis Stock Underperforming the Dow?

Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

RDY : 13.78 (-2.89%)
ZTS : 119.04 (+0.33%)
$DOWI : 47,718.08 (-0.49%)
Zoetis and Surgery Partners Shares Are Soaring, What You Need To Know

Zoetis and Surgery Partners Shares Are Soaring, What You Need To Know

ZTS : 119.04 (+0.33%)
SGRY : 17.11 (-0.47%)
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph,...

ZTS : 119.04 (+0.33%)
Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings?

Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings?

ZTS : 119.04 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified...

See More

Key Turning Points

3rd Resistance Point 123.36
2nd Resistance Point 122.35
1st Resistance Point 120.50
Last Price 119.04
1st Support Level 117.64
2nd Support Level 116.62
3rd Support Level 114.77

See More

52-Week High 181.85
Fibonacci 61.8% 156.41
Fibonacci 50% 148.55
Fibonacci 38.2% 140.69
Last Price 119.04
52-Week Low 115.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar